Literature DB >> 7747519

[Mumps vaccines: virological basis].

A Ströhle1, D Germann.   

Abstract

The prevention of mumps virus infection relies on the application of live, attenuated mumps virus vaccines. The process of attenuation from a wildtype mumps isolate to a safe vaccine has been empirical. A lower degree of attenuation results in solid immunity but carries an increased risk of post-vaccination meningitis due to the vaccine strain. Currently used vaccine strains are highly attenuated and essentially free of vaccine strain induced disease. However, their immunogenicity may be lower than previously reported.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7747519     DOI: 10.1007/BF01360324

Source DB:  PubMed          Journal:  Soz Praventivmed        ISSN: 0303-8408


  52 in total

1.  Polypeptides of mumps virus.

Authors:  S C Jensik; S Silver
Journal:  J Virol       Date:  1976-02       Impact factor: 5.103

2.  Sequence variation of the P gene among mumps virus strains.

Authors:  A Yamada; K Takeuchi; K Tanabayashi; M Hishiyama; A Sugiura
Journal:  Virology       Date:  1989-09       Impact factor: 3.616

3.  Protective effects of glycoprotein-specific monoclonal antibodies on the course of experimental mumps virus meningoencephalitis.

Authors:  J S Wolinsky; M N Waxham; A C Server
Journal:  J Virol       Date:  1985-03       Impact factor: 5.103

4.  Frequency of true adverse reactions to measles-mumps-rubella vaccine. A double-blind placebo-controlled trial in twins.

Authors:  H Peltola; O P Heinonen
Journal:  Lancet       Date:  1986-04-26       Impact factor: 79.321

5.  Punctuated equilibrium and positive Darwinian evolution in vesicular stomatitis virus.

Authors:  S T Nichol; J E Rowe; W M Fitch
Journal:  Proc Natl Acad Sci U S A       Date:  1993-11-15       Impact factor: 11.205

6.  Matrix protein gene sequence of vaccine and vaccine-associated strains of mumps virus.

Authors:  M A Afzal; A R Pickford; P J Yates; T Forsey; P D Minor
Journal:  J Gen Virol       Date:  1994-05       Impact factor: 3.891

7.  Clinical mumps vaccine efficacy.

Authors:  R Kim-Farley; S Bart; H Stetler; W Orenstein; K Bart; K Sullivan; T Halpin; B Sirotkin
Journal:  Am J Epidemiol       Date:  1985-04       Impact factor: 4.897

8.  Cell-mediated immune response to mumps virus infection in man.

Authors:  Y Chiba; J L Dzierba; A Morag; P L Ogra
Journal:  J Immunol       Date:  1976-01       Impact factor: 5.422

9.  Duration of the immune response to MMR vaccine in children of two age-different groups.

Authors:  S Li Volti; G Giammanco-Bilancia; M Grassi; R Garozzo; R Gluck; G Giammanco
Journal:  Eur J Epidemiol       Date:  1993-05       Impact factor: 8.082

10.  A controlled trial for evaluating two live attenuated mumps-measles vaccines (Urabe Am 9-Schwarz and Jeryl Lynn-Moraten) in young children.

Authors:  T Popow-Kraupp; M Kundi; F Ambrosch; H Vanura; C Kunz
Journal:  J Med Virol       Date:  1986-01       Impact factor: 2.327

View more
  1 in total

1.  Fully vaccinated children are rare: immunization coverage and seroprevalence in Austrian school children.

Authors:  Markus Ringler; Georg Göbel; Johannes Möst; Kurt Weithaler
Journal:  Eur J Epidemiol       Date:  2003       Impact factor: 8.082

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.